iPPI-DB

Inhibitors of Protein-Protein Interaction Database

Compound 2105

Identifiers

  • Canonical SMILES: 
    CC[C@@H]1NC(=O)C([CH]CCNC(N)=N)NC(=O)[C@@](C)(CCCCCCCCNC(=O)[C@H](NC1=O)c1ccccc1)NC(=O)C(C)C
  • IUPAC name: 
    3-carbamimidamido-1-[(5S,8R,19R)-5-ethyl-19-methyl-19-(2-methylpropanamido)-3,6,9,20-tetraoxo-8-phenyl-1,4,7,10-tetraazacycloicosan-2-yl]propyl
  • InChi: 
    InChI=1S/C33H53N8O5/c1-5-24-28(43)40-26(23-16-11-10-12-17-23)30(45)36-20-14-9-7-6-8-13-19-33(4,41-27(42)22(2)3)31(46)39-25(29(44)38-24)18-15-21-37-32(34)35/h10-12,16-18,22,24-26H,5-9,13-15,19-21H2,1-4H3,(H,36,45)(H,38,44)(H,39,46)(H,40,43)(H,41,42)(H4,34,35,37)/t24-,25?,26+,33+/m0/s1
  • InChiKey: 
    PWVZQWAQCMDYLO-FGWOXDHBSA-N

External search

Bibliography (1)

Publication Name
Karatas Hacer, Li Yangbing, Liu Liu, Ji Jiao, Lee Shirley, Chen Yong, Yang Jiuling, Huang Liyue, Bernard Denzil, Xu Jing, Townsend Elizabeth C., Cao Fang, Ran Xu, Li Xiaoqin, Wen Bo, Sun Duxin, Stuckey Jeanne A, Lei Ming, Dou Yali, Wang Shaomeng. . Discovery of a Highly Potent, Cell-Permeable Macrocyclic Peptidomimetic (MM-589) Targeting the WD Repeat Domain 5 Protein (WDR5)–Mixed Lineage Leukemia (MLL) Protein–Protein Interaction Journal of Medicinal Chemistry. 17

Pharmacological data

Biochemical tests Cellular tests PK tests Cytotoxicity tests
3 2 0 0

Targets

PPI family Best activity Diseases MMoA
WDR5/MLL 9.00 lymphoid leukemia (disease) Inhibition
Physicochemical filters
Descriptor Lipinski's RO5 Veber Pfizer's 3/75
Compliance
MW 641.41 g/mol
HBA 13
HBD 9
HBA + HBD 22
AlogP 1.38
TPSA 209.14
RB 8
Radar chart
PCA : iPPI-DB chemical space
PCA : Correlation circle
Efficiencies: iPPI-DB biplot LE versus LLE
Summary
Bibliographic ressources Biochemical tests Cellular tests PK tests Cytotoxicity tests
1 3 2 0 0
Pharmacological data
Bibliography Name Target Competition Assay type Assay name Cell line Activity type Activity
10.1021/acs.jmedchem.6b01796 17 KMT2A
Q03164 		WDR5
P61964 		Biochemical assay Fluorescence Polarization pIC50 (half maximal inhibitory concentration, -log10) 8.89
10.1021/acs.jmedchem.6b01796 17 KMT2A
Q03164 		WDR5
P61964 		Biochemical assay Fluorescence Polarization pKi (inhibition constant, -log10) 9.00
10.1021/acs.jmedchem.6b01796 17 KMT2A
Q03164 		WDR5
P61964 		Biochemical assay AlphaLISA pIC50 (half maximal inhibitory concentration, -log10) 6.13
10.1021/acs.jmedchem.6b01796 17 KMT2A
Q03164 		WDR5
P61964 		Cellular assay cell growth inhibition MOLM-13 MOLM-13 pIC50 (half maximal inhibitory concentration, -log10) 4.67
10.1021/acs.jmedchem.6b01796 17 KMT2A
Q03164 		WDR5
P61964 		Cellular assay cell growth inhibition MV4-11 MV4-11 pIC50 (half maximal inhibitory concentration, -log10) 5.12
Ta Structure Name Drugbank ID
0.7521 CR665 DB05155
0.7076 D-phenylalanyl-N-benzyl-L-prolinamide DB07143
0.6949 PZ-128 DB11839
0.6857 N-cyclooctylglycyl-N-(4-carbamimidoylbenzyl)-L-prolinamide DB06858
0.6818 D-phenylalanyl-N-(3-methylbenzyl)-L-prolinamide DB07133
0.6814 D-phenylalanyl-N-{4-[amino(iminio)methyl]benzyl}-L-prolinamide DB07005
0.6814 (R)-Praziquantel DB11749
0.6814 Praziquantel DB01058
0.6792 N-cycloheptylglycyl-N-(4-carbamimidoylbenzyl)-L-prolinamide DB06853
0.6792 (S)-N-(4-carbamimidoylbenzyl)-1-(3-cyclopentylpropanoyl)pyrrolidine-2-carboxamide DB07095
0.6792 (S)-N-(4-carbamimidoylbenzyl)-1-(3-cyclohexylpropanoyl)pyrrolidine-2-carboxamide DB07131
0.6698 (S)-N-(4-carbamimidoylbenzyl)-1-(2-(cyclohexylamino)ethanoyl)pyrrolidine-2-carboxamide DB06850
0.6667 1-[(2R)-2-aminobutanoyl]-N-(4-carbamimidoylbenzyl)-L-prolinamide DB06947
0.6667 D-leucyl-N-(4-carbamimidoylbenzyl)-L-prolinamide DB06996
0.6667 3-cyclohexyl-D-alanyl-N-(3-chlorobenzyl)-L-prolinamide DB07190